Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.Donate to our crowdfunder
Atezolizumab is not currently routinely available on the National Health Service for breast cancer patients with PD-L1-positive, triple-negative, advanced breast cancer. The National Institute for Health and Care Excellence (NICE) is currently developing recommendations on the use of atezolizumab for this indication through its appraisal programme and published its draft guidance for consultation in October 2019. NICE’s appraisal has been delayed while commercial discussions with the company, Roche, are ongoing. NICE will aim to publish its guidance on the use of atezolizumab as soon as possible following the completion of their commercial discussions. If NICE is able to recommend use of the drug following the commercial discussions, atezolizumab will be eligible for funding through the Cancer Drugs Fund from the point of NICE’s draft guidance. If NICE is able to recommend use of atezolizumab it will be routinely funded by NHS England and NHS Improvement for NHS patients in line with NICE’s recommendations.